Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan r
Complement deposition on platelets identifies a biologically distinct subset of adult ITP associated with higher platelet turnover and more first-line treatment refractoriness.
A French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.
This review synthesizes the ASC4OPT trial results alongside pivotal evidence from the ASCEMBL and ASC4FIRST studies, evaluating the role of the STAMP inhibitor asciminib in chronic myeloid leukemia across multiple treatment lines.
The 2/20/20 risk stratification model identifies a smaller, truly high-risk SMM group with higher progression rates than the AQUILA trial criteria, suggesting better targeting for early intervention.
A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for
This study identifies late-onset sex chromosome loss as a critical biomarker for predicting relapse and survival outcomes in patients following sex-mismatched stem cell transplantation.
This clinical review evaluates the superior efficacy of intravenous ferumoxytol over oral iron for treating gestational anemia, analyzing hematologic recovery and maternal outcomes based on the latest RCT evidence.
This review examines the impact of myeloproliferative control on survival in advanced CMML, highlighting the prognostic value of stringent cytoreduction and novel flow cytometric biomarkers such as classical monocytes and immature granulocy
The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
A multicenter study reveals that menstrual pain and abnormal uterine bleeding are highly prevalent in women with sickle cell disease and are linked to increased hospitalizations. Low awareness of hormonal therapies highlights a critical gap
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering